fatty liver disease

Showing 2 posts of 2 posts found.


Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

February 12, 2019
Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …


Gilead’s drug boosted by positive Phase II trials and aims to move forward

October 21, 2016
Medical Communications Gilead, Gilead Sciences, clinical trials, fatty liver disease

Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The …

Latest content